Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Inv. presentation
Quarterly results

Rallybio Corp (RLYB) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "Rallybio Reports Second Quarter 2023 Financial Results and Provides Business Updates"
06/29/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Head of Investor Relations and Corporate Communications"
05/19/2023 4 PARMAR KUSH (Director) has filed a Form 4 on Rallybio Corp
Txns: Granted 15,490 options to buy @ $5.64, valued at $87.4k
05/19/2023 4 Nash Christine A (Director) has filed a Form 4 on Rallybio Corp
Txns: Granted 15,490 options to buy @ $5.64, valued at $87.4k
05/19/2023 4 Boudreau Helen M (Director) has filed a Form 4 on Rallybio Corp
Txns: Granted 15,490 options to buy @ $5.64, valued at $87.4k
05/19/2023 4 Hopfner Robert Lorne (Director) has filed a Form 4 on Rallybio Corp
Txns: Granted 15,490 options to buy @ $5.64, valued at $87.4k
05/19/2023 4 Soteropoulos Paula (Director) has filed a Form 4 on Rallybio Corp
Txns: Granted 15,490 options to buy @ $5.64, valued at $87.4k
05/19/2023 4 Liu Hui (Director) has filed a Form 4 on Rallybio Corp
Txns: Granted 15,490 options to buy @ $5.64, valued at $87.4k
05/19/2023 4 HUNT RONALD (Director) has filed a Form 4 on Rallybio Corp
Txns: Granted 15,490 options to buy @ $5.64, valued at $87.4k
05/19/2023 4 Chung Wendy (Director) has filed a Form 4 on Rallybio Corp
Txns: Granted 12,353 options to buy @ $5.64, valued at $69.7k
05/15/2023 EFFECT Form EFFECT - Notice of Effectiveness:
05/12/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
05/10/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/09/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Rallybio Reports First Quarter 2023 Financial Results -- RLYB212 Phase 1b Proof-of-Concept Study Results to be Presented at 31st Congress of the International Society of Thrombosis and Haemostasis in June 2023 -- -- Phase 1 Multiple Dose Cohort RLYB212 Study Initiated in 1Q 2023; Data Expected in 4Q 2023 -- -- Phase 1 Multiple Ascending Dose Study of RLYB116 Continues to Progress; Safety, PK and PD Data Expected in 4Q 2023 -- -- $150.4 million cash, cash equivalents and marketable securities as of March 31, 2023; Provides Runway into 1Q 2025 --"
03/16/2023 4 Lieber Jonathan I (See Remarks) has filed a Form 4 on Rallybio Corp
Txns: Bought 5,000 shares @ $5.21, valued at $26.1k
03/09/2023 4 PARMAR KUSH (Director) has filed a Form 4 on Rallybio Corp
Txns: Sold 100,000 shares @ $8.2, valued at $820k
03/09/2023 4 5AM Partners V, LLC (10% Owner) has filed a Form 4 on Rallybio Corp
Txns: Sold 100,000 shares @ $8.2, valued at $820k
03/06/2023 10-K Annual Report for the period ended December 31, 2022
03/06/2023 8-K Quarterly results
Docs: "Rallybio Reports Fourth Quarter and Full Year 2022 Financial Results -- Proof-of-Concept Achieved for RLYB212; Showed Rapid and Complete Elimination of Transfused HPA-1a Positive Platelets in HPA-1a Negative Subjects – -- Phase 1 Multiple Dose Cohort RLYB212 Study Initiated -- -- Phase 1 Multiple Ascending Dose Study of RLYB116 Continues to Progress; Safety, PK and PD Data Expected in 4Q 2023 -- -- $169.0 million cash, cash equivalents and marketable securities as of December 31, 2022; Provides Runway into 1Q 2025-- NEW HAVEN, Conn. March 6, 2023-- Rallybio Corporation , a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported financial results for the fourth qu...",
"Rallybio Announces Proof-of-Concept Achieved for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia -- RLYB212 Showed Rapid Elimination of Transfused, HPA-1a Positive Platelets in HPA-1a Negative Subjects -- -- Clinical Findings and Safety Profile Consistent with Previously Reported Data; Continue to Support the Potential for RLYB212 as a Prophylactic Treatment for FNAIT -- -- Company Expects to Present Results at a Scientific Conference in 2023 --"
02/09/2023 SC 13G/A FMR LLC reports a 8.6% stake in RALLYBIO CORP
02/06/2023 4 Uden Stephen (See Remarks) has filed a Form 4 on Rallybio Corp
Txns: Granted 214,000 options to buy @ $6.5, valued at $1.4M
02/06/2023 4 Ryder Steven (Chief Medical Officer) has filed a Form 4 on Rallybio Corp
Txns: Granted 119,000 options to buy @ $6.5, valued at $773.5k
02/06/2023 4 MACKAY MARTIN (CEO) has filed a Form 4 on Rallybio Corp
Txns: Granted 214,000 options to buy @ $6.5, valued at $1.4M
02/06/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/01/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/01/2023 3 Lieber Jonathan I (See Remarks) has filed a Form 3 on Rallybio Corp
02/01/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/31/2023 8-K Quarterly results
01/23/2023 SC 13G/A Tekla Capital Management LLC reports a 4.6% stake in Rallybio Corp.
01/05/2023 4 Liu Hui (Director) has filed a Form 4 on Rallybio Corp
Txns: Granted 10,237 options to buy @ $6.19, valued at $63.4k
01/05/2023 4 PARMAR KUSH (Director) has filed a Form 4 on Rallybio Corp
Txns: Granted 10,344 options to buy @ $6.19, valued at $64k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy